Immunoreactive macrophage colony-stimulating factor is increased in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits after recombinant human macrophage colony-stimulating factor therapy.

Infiltration of monocytes into arteries is an early event in the pathogenesis of atherosclerosis. This recruitment is interpreted as enhancing lesion development, but it could also be a host response limiting lipid accumulation. The ability of macrophages to limit cholesterol uptake, however, can be reduced by the impaired mobility and metabolic activity associated with foam cell development. As lesions enlarge, foam cells die and become the nidus for the necrotic core. Treatments to improve viability might improve foam cell function and promote regression. Macrophage colony-stimulating factor (M-CSF) is vital to monocyte/macrophage differentiation, proliferation, and activation. We found that foam cells of Watanabe heritable hyperlipidemic (WHHL) rabbits had faint staining for M-CSF. Treatment of rabbits with recombinant human M-CSF (rhM-CSF) increased M-CSF staining, which correlated with reduced cholesterol content of these foam cells.

Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion.

The progression of a lesion from ischemic injury to infarct, after the permanent occlusion of a middle cerebral artery, may be influenced by the influx of leukocytes into the ischemic territory. We aimed to evaluate the effectiveness of treating rats that had permanent middle cerebral artery occlusion with a single dose of an anti-CD11b/18 monoclonal antibody injected 1 hour after the arterial occlusion. To mimic the clinical situation of patients with ischemic strokes who may be treated within 1 hour of the ischemic event, the artery remained occluded. Forty-one adult Wistar rats had permanent middle cerebral artery occlusion, and one was subjected to a sham operation. One hour later, 22 rats received CD11b/18 monoclonal antibody and an additional 20 were injected either with a nonspecific antibody (n = 10) or a buffer solution (n = 10). Experiments were terminated at intervals ranging 12 to 96 hours after the arterial occlusion. Endpoints included neurological testing, daily evaluation of body weight, counts of white blood cells in the peripheral blood, measurement of the area of pallor in the ischemic hemisphere, counts of necrotic neurons, and counts of leukocytes sequestered in the ischemic hemisphere. In experiments terminated 12 hours after the arterial occlusion (n = 4), there were fewer necrotic neurons in the group treated with the CD11b/18 monoclonal antibody compared with the two controls (P < .05), but this difference was not reflected in the neurological scores. Numbers of necrotic neurons in experiments terminated > 12 hours later were not different among the three subgroups. White blood cell counts in peripheral blood were lower in animals with arterial occlusion injected with the monoclonal antibody CD11b/18 (P < .05); numbers of leukocytes sequestered in the ischemic hemisphere were not different in the three groups. Neither changes in body weight nor in the volume of the area of pallor were significantly different among the three groups.

Adenoviral-mediated gene transfer to bladder in vivo.

This study was designed to examine the potential for gene therapy in bladder in vivo using adenoviral vectors. Gene transfer to rat bladders was accomplished via direct intravesical instillation using a replication-defective adenoviral vector containing a marker gene encoding for Escherichia coli beta-galactosidase (beta-gal). Successful gene transfer was confirmed by analyzing bladder samples for DNA and RNA using polymerase chain reaction (PCR) with primers specific for beta-gal and adeno sequences, detecting beta-gal in full-thickness bladder wall using specific histochemical staining (X-gal) and documenting recombinant protein production. Bladder architecture was preserved, without evidence of distant spread of virus as assessed by PCR. Gene expression was evident for at least 7 days. In summary, bladder cells can be genetically altered using replication-deficient adenoviral vectors via simple intravesical instillation of vector. Introduction of exogenous genetic material is a potentially powerful therapeutic modality for immunomodulation of bladder neoplasms.

Recombinant human macrophage colony-stimulating factor reduces plasma cholesterol and carrageenan granuloma foam cell formation in Watanabe heritable hyperlipidemic rabbits.

Previous studies have demonstrated that short-term administration of recombinant human macrophage colony-stimulating factor (rhM-CSF) reduces plasma cholesterol in rabbits, nonhuman primates, and human subjects. This study extended the dose schedule of rhM-CSF to 8 weeks of continuous intravenous infusion (CIV) in the Watanabe heritable hyperlipidemic (WHHL) rabbit and expanded the scope to include an assessment of macrophage-derived foam cell development. Ten male WHHL rabbits were injected subcutaneously with 1% carrageenan to promote formation of a macrophage-rich foam cell granuloma. Rabbits were infused with either vehicle or rhM-CSF at 100 micrograms/kg per day (weeks 1 through 5) followed by 300 micrograms/kg per day (weeks 6 through 8). rhM-CSF (100 micrograms/kg per day) decreased total plasma cholesterol by 45% at 2 weeks compared with controls. The gradual return of plasma cholesterol toward control concentrations over the subsequent 3 weeks correlated with the appearance of circulating antibodies specific to rhM-CSF. Granuloma weights at harvest (8 weeks after infusion) were significantly lower (2.8 +/- 0.7 g, mean +/- SEM) in rhM-CSF-treated rabbits relative to controls (7.1 +/- 1.5 g, P < .05). Granulomas from rabbits treated with rhM-CSF contained lower concentrations of cholesterol (2.0 +/- 0.7 versus 6.1 +/- 1.5 micrograms/mg, P < .03) and cholesteryl ester (0.7 +/- 0.4 versus 3.9 +/- 1.2 micrograms/mg, P < .03) than controls. Histological evaluation revealed that granulomas from the rhM-CSF-treated rabbits were more fibrous and contained fewer foam cells than those from controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Desipramine effects on cocaine self-administration by rhesus monkeys.

The effects of desipramine treatment (0.56-10.0 mg/kg per day) on cocaine self-administration were compared to saline treatment in five rhesus monkeys. Cocaine (0.050 or 0.100 mg/kg per inj) and food (1 g banana pellets) self-administration were maintained on an FR 4 (VR 16:S) reinforcement schedule. Desipramine (or an equal volume saline control solution) was infused over 1 h each day through the second lumen of an intravenous catheter. After 5 days of baseline saline treatment, seven doses of desipramine each were administered for 5 days in an ascending order. Cocaine self-administration increased (P less than 0.01) or remained equivalent to base-line levels in 4 of 5 subjects during the first 15 days of desipramine treatment (0.56 to 1.78 mg/kg per day). Three monkeys continued to self-administer cocaine equivalent to or significantly above base-line levels (P less than 0.01) during days 16-30 of desipramine treatment (3.2-7.86 mg/kg per day). The highest desipramine dose (10 mg/kg per day) significantly suppressed cocaine self-administration in only one of these three monkeys (P less than 0.01). Desipramine treatment (3.2-10.0 mg/kg per day) suppressed cocaine self-administration (P less than 0.01) without a concomitant suppression of food-maintained responding in one of five subjects. A generalized suppression of both cocaine and food-maintained responding (P less than 0.01) during desipramine treatment occurred in one monkey that took the highest base-line levels of cocaine (6.3 +/- 1.03 mg/kg per day). Food-maintained responding remained equivalent to or significantly above (P less than 0.01) base-line levels in four of five monkeys during desipramine treatment. A transient decrease in food self-administration at desipramine doses of 1.78-5.62 mg/kg per day occurred in one monkey (P less than 0.01). Thirty days of desipramine treatment at the highest doses (5.62, 7.86 and 10.0 mg/kg per day for 10 days each) also did not suppress cocaine self-administration in a monkey that took an average of 4 mg/kg per day of cocaine during saline base-line treatment. These primate data are concordant with the extant clinical literature on the inconsistent effects of desipramine treatment; i.e., both stimulation of cocaine use and inconsistent or incomplete attenuation of cocaine abuse during desipramine maintenance have been reported.

Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys.

The effects of daily treatment with buprenorphine (0.237-0.70 mg/kg/day), naltrexone (0.32-3.20 mg/kg/day) and saline on cocaine self-administration were compared in rhesus monkeys. Cocaine (0.05 or 0.10 mg/kg/injection) and food (1-g banana pellets) self-administration were maintained on a fixed-ratio 4 (variable ratio 16:S) schedule of reinforcement. Buprenorphine, naltrexone or an equal volume saline control solution were infused slowly over 1 hr through one lumen of a double lumen i.v. catheter at the same time each day. Saline and each dose of buprenorphine (0.237, 0.40 and 0.70 mg/kg/day) or naltrexone (0.32 and 3.20 mg/kg/day) were studied for 60 sessions over 15 consecutive days. Buprenorphine significantly suppressed cocaine self-administration (P less than .001-.0001) in comparison to saline in all monkeys. Cocaine self-administration decreased by 49 to 95% in five of six monkeys on the 1st day of buprenorphine administration (0.237 and 0.40 mg/kg/day) and remained suppressed by an average of 72 to 93% during buprenorphine treatment. After abrupt termination of buprenorphine treatment (0.237 and 0.70 mg/kg/day), cocaine self-administration remained suppressed for an average of 16 +/- 4.4 and 28 +/- 6.6 days, respectively. Buprenorphine (0.237 and 0.40 mg/kg/day) initially suppressed food self-administration in some monkeys (P less than .01), but tolerance developed to buprenorphine's effects on food-maintained responding whereas cocaine self-administration remained significantly suppressed. During treatment with 0.70 mg/kg/day of buprenorphine, food self-administration returned to or significantly exceeded (P less than .01) base-line levels in three animals. Daily patterns of food self-administration were not disrupted by buprenorphine treatment. Naltrexone (0.32 mg/kg/day) initially suppressed cocaine self-administration by an average of 28% over 15 days (P less than .0009). During high-dose naltrexone treatment (3.20 mg/kg/day), cocaine-maintained responding was suppressed by 25% over 15 days (P less than .01). Cocaine-maintained responding was not significantly changed by naltrexone in one of the five subjects. Food self-administration decreased by 24% (P less than .05) after 5 days of 0.32 mg/kg of naltrexone administration, then exceeded baseline levels during 3.20 mg/kg of naltrexone administration. These data suggest that buprenorphine decreases cocaine's reinforcing properties more effectively than naltrexone across the dose-range studied. Buprenorphine may be an effective pharmacotherapy for treatment of cocaine abuse as well as dual abuse of cocaine plus heroin.

Extraosseous osteosarcoma in a nonhuman primate (Macaca mulatta).

A case of a very rare malignant bone-forming sarcoma, which was located in the soft tissue but had no anatomic attachment to bone, is presented. This tumor originated in the subcuticular tissue over the right scapula and was histologically composed of sheets of anaplastic spindle cells that produced osteoid. The tumor recurred twice before the animal was killed. The recurrent masses produced less osteoid and were generally less differentiated histologically than the initial tumor.

Buprenorphine suppresses cocaine self-administration by rhesus monkeys.

Cocaine abuse has reached epidemic proportions in the United States, and the search for an effective pharmacotherapy continues. Because primates self-administer most of the drugs abused by humans, they can be used to predict the abuse liability of new drugs and for preclinical evaluation of new pharmacotherapies for drug abuse treatment. Daily administration of buprenorphine (an opioid mixed agonist-antagonist) significantly suppressed cocaine self-administration by rhesus monkeys for 30 consecutive days. The effects of buprenorphine were dose-dependent. The suppression of cocaine self-administration by buprenorphine did not reflect a generalized suppression of behavior. These data suggest that buprenorphine would be a useful pharmacotherapy for treatment of cocaine abuse. Because buprenorphine is a safe and effective pharmacotherapy for heroin dependence, buprenorphine treatment may also attenuate dual abuse of cocaine and heroin.

Alcohol effects on LH and FSH in ovariectomized female monkeys.

The acute effects of alcohol (2.5, 3.0, 3.5 g/kg) and sucrose control solution on basal levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were compared in recently and chronically ovariectomized female rhesus monkeys. Integrated plasma samples were collected at 20 min intervals for 3 hr before and 6 hr after nasogastric intubation of alcohol or isocaloric sucrose control solution. Baseline levels of LH and FSH were significantly higher in recently than in chronically ovariectomized females (p less than 0.001). Baseline LH pulse frequency was also significantly higher (p less than 0.001) in the recently ovariectomized group than in the chronically ovariectomized group (0.704 +/- 0.03 vs. 0.379 +/- 0.10 pulses/hr). FSH pulse frequency was equivalent in both groups (0.444 +/- 0.06 to 0.360 +/- 0.06 pulses/hr). After 2.5 g/kg of alcohol, peak blood alcohol levels were 243 to 256 mg/dl and LH decreased significantly (p less than 0.01) in both groups. After 3.0 g/kg alcohol, peak blood alcohol levels were 237 to 289 mg/dl, and basal LH levels (p less than 0.05) and LH pulse frequency (p less than 0.05) decreased significantly only in the recently ovariectomized group. After 3.5 g/kg of alcohol, peak blood alcohol levels exceeded 320 mg/dl, and LH did not change significantly in either group. Administration of 3.5 g/kg alcohol was associated with increased LH pulse amplitude in some individuals. Since lower alcohol doses (2.5 and 3.0 g/kg) and sucrose control administration were followed by a significant decline in LH (p less than 0.05-0.01) and the highest alcohol dose (3.5 g/kg) was not, these data suggest the possible influence of nonspecific "stress" on modulation of LH secretory activity. FSH did not change after sucrose administration in recently ovariectomized monkeys, but was significantly suppressed after 2.5 and 3.5 g/kg alcohol (p less than 0.05). In the chronically ovariectomized monkeys, FSH decreased significantly after administration of sucrose and all alcohol doses. LH suppression was not consistently associated with changes in FSH in either group--a finding consonant with the hypothesis that LH and FSH may be controlled by different hypothalamic regulatory factors.

Alcohol self-administration by female macaque monkeys: a model for study of alcohol dependence, hyperprolactinemia and amenorrhea.

Chronic alcohol dependence produces persistent amenorrhea in alcoholic women and female Macaque monkeys but the mechanism is unknown. In one amenorrheic alcohol-dependent monkey, prolactin levels increased from 16.5 to 63 ng/ml during chronic, high-dose alcohol self-administration (3.4 g/kg/day) and immunocytochemical examination of the anterior pituitary showed apparent hyperplasia of the lactotrophs. These data suggested that hyperprolactinemia might contribute to alcohol-induced amenorrhea. Four amenorrheic cycles (85-194 days) from two other alcoholic female monkeys that self-administered an average of 2.97 to 4.4 g/kg/day of alcohol were also studied. Each monkey became amenorrheic during the first menstrual cycle that alcohol was available. One monkey developed galactorrhea during a 97-day amenorrheic cycle when alcohol self-administration averaged 3.35 g/kg/day. Although prolactin levels were intermittently elevated above 20 ng/ml, average levels during these amenorrheic cycles (14.7 +/- 1.8 to 19.6 +/- 1.5 ng/ml) did not differ significantly from prolactin levels during normal ovulatory menstrual cycles when no alcohol was available (19.7 +/- 0.36 ng/ml). There was a negative correlation between daily alcohol dose and prolactin levels (p less than .01). High-dose alcohol self-administration was often associated with low normal prolactin levels, but a relative fall in alcohol dose was usually associated with elevated prolactin levels. These data suggest that both alcohol intoxication and relative alcohol withdrawal may alter basal prolactin levels. LH levels were significantly lower during amenorrheic cycles (16.9 +/- 1.2 to 24 +/- 1.4 ng/ml) than during nonalcohol control cycles (28 +/- 1.2 to 30 +/- 2.2 ng/ml) (p less than .001). These data are consistent with clinical data that suggest that hypothalamic amenorrhea is associated with suppression of gonadotropin secretory activity.

Naltrexone effects on pituitary and gonadal hormones in male and female rhesus monkeys.

The long-acting opioid antagonist, naltrexone, stimulates LH and FSH in women during the early follicular phase of the menstrual cycle and is a new provocative test of hypothalamic-pituitary function (42,63). The acute effects of naltrexone (0.25, 0.50 and 1.0 mg/kg IV) on anterior pituitary (LH, FSH, PRL) and gonadal steroid (T or E2) hormones were studied in 7 female and 4 male rhesus monkeys (Macaca mulatta). Integrated plasma samples were collected at 20 min intervals for 60 min before and for 300 min after intravenous infusion of naltrexone over 10 min. In females studied during the early follicular phase (cycle days 1-3), naltrexone did not stimulate LH and significantly suppressed E2 (p less than 0.0003-0.0001) and FSH (p less than 0.006-0.0001). Naltrexone (0.50 and 1.0 mg/kg) also did not stimulate LH release in late follicular phase females (cycle days 10-12) when estradiol levels were in the peri-ovulatory range. FSH and E2 were significantly suppressed (p less than 0.01-0.05) after 1.0 mg/kg naltrexone, but not after 0.5 mg/kg naltrexone. However, in males all doses of naltrexone significantly stimulated LH (p less than 0.003-0.0001) and T (p less than 0.001-0.0001) but not FSH. LH increased significantly above baseline within 20 to 40 min and T increased significantly within 60 min. These gender differences in naltrexone's effects on pituitary gonadotropins and gonadal steroid hormones were unanticipated. These data are not concordant with clinical studies which report significant naltrexone stimulation of LH in men and in women during the early follicular phase.(ABSTRACT TRUNCATED AT 250 WORDS)

Differential tolerance development to buprenorphine-, diprenorphine-, and heroin-induced disruption of food-maintained responding in macaque monkeys.

Single daily subcutaneous injections of buprenorphine (1.0 mg/kg), diprenorphine (1.0 mg/kg), or heroin (1.0 mg/kg) were given over 25 consecutive days to examine the degree and the rate of tolerance development to drug-induced suppression of food maintained responding. One gram food pellets were available on a second order schedule (FR 4 VR 16: S) during the 1-hr sessions three times a day. All drug and saline control injections were given at 10:00 a.m., 1 hr before a food session. During the first three days of treatment all three drugs produced marked suppression of food-maintained performance. Recovery from buprenorphine- and diprenorphine-induced suppression of food-maintained responding occurred within four and eight days, respectively. By the 25th day of buprenorphine and diprenorphine treatment, operant responding for food increased significantly above control levels (p less than 0.01). In contrast, the significant heroin-induced disruption of food-maintained responding (p less than 0.01) persisted throughout the 25-day treatment period. Saline substitution for all three drugs resulted in a gradual return to control levels of food pellets earned. Linear regression analysis of the linear portion of the time-effect curve revealed significant differences in both the rate and the degree of tolerance development to these three drugs. These differences in tolerance development may reflect pharmacokinetic differences between the relatively short-acting heroin and the longer-acting diprenorphine and buprenorphine.

Alcohol effects on naloxone-stimulated luteinizing hormone, follicle-stimulating hormone and prolactin plasma levels in female rhesus monkeys.

Alcohol's effects on hypothalamic function were examined under conditions of opioid antagonist stimulation. The effects of naloxone (0.5 mg/kg i.v.) on anterior pituitary hormone plasma levels after alcohol (2.5 and 3.5 g/kg) or sucrose control administration were studied in 10 normal female monkeys (Macaca mulatta) during the luteal phase of the menstrual cycle. Naloxone was administered 60 or 90 min after nasogastric alcohol administration when blood alcohol levels were above 120 and 140 mg/dl. The rate of naloxone infusion (i.v. bolus or slowly over 10 min) and basal levels of progesterone were critical determinants of the anterior pituitary response to opioid antagonist stimulation. Bolus administration of naloxone did not stimulate luteinizing hormone (LH) or follicle-stimulating hormone (FSH) under control or alcohol conditions. Slow naloxone infusion significantly stimulated LH (P less than .01-.05), but not FSH, in monkeys with high basal progesterone levels (14.1-15.8 ng/ml) under both control and alcohol conditions. Naloxone stimulation of LH was equivalent under control and 2.5 g/kg alcohol conditions (60 and 53% above base line). The LH response to naloxone was enhanced after administration of 3.5 g/kg alcohol and increased to 151% above base line (P less than .01) in monkeys with high progesterone levels. In monkeys with low progesterone levels (3.6-4.6 ng/ml), slow naloxone infusion did not stimulate LH or FSH after sucrose control or 3.5 g/kg alcohol administration, but LH increased (P less than .05) after 2.5 g/kg alcohol administration. A slow infusion of naloxone suppressed PRL levels significantly below base line after sucrose and alcohol administration in monkeys with high (P less than .01-.0002) and low progesterone levels (P less than .0001). Naloxone suppression of PRL was equivalent after alcohol and sucrose control administration. Alcohol alone did not suppress PRL levels significantly. We conclude that acute alcohol administration, with peak blood alcohol levels above 240 and 300 mg/dl, does not attenuate hypothalamic and pituitary responsivity to naloxone stimulation.

Progressive ratio performance maintained by buprenorphine, heroin and methadone in Macaque monkeys.

The relative reinforcing efficacy of buprenorphine (0.01-0.10 mg/kg/inj.), heroin (0.01-0.10 mg/kg/inj.), methadone (0.03-0.25 mg/kg/inj.) and saline were compared in Macaque male monkeys using progressive ratio procedures. Responding for drugs and food (1 g banana pellet) was maintained on a second order FR 4 (VR 16:S) schedule of reinforcement that required an average of 64 responses for each injection or food pellet. After 40 sessions (10 days) of stable performance, the number of responses for each drug injection was systematically increased until monkeys reached a breakpoint defined by 2 consecutive days of no drug injections. Progressive ratio breakpoints for heroin at intermediate and high doses (0.05 and 0.10 mg/kg/inj.) were two to three times higher than for any other drug (P less than 0.05). Breakpoints for buprenophine (0.01-0.10 mg/kg/inj.) were higher than for a low dose of methadone (0.03 mg/kg/inj.) but were equivalent to an intermediate methadone dose (0.10 mg/kg/inj.). Breakpoints for both low (0.01 mg/kg/inj.) and high (0.10 mg/kg/inj.) buprenorphine doses were greater than for intermediate doses (0.03 and 0.05 mg/kg/inj.) but these differences were not statistically significant. Linear regression and area under the curve analyses were used to quantify the rate at which drug maintained responding decreased by 30% of control levels as response requirements were increased. Extrapolated breakpoints derived from linear regression analyses were significantly correlated (P less than 0.05-0.01) with actual breakpoints for buprenorphine, heroin and methadone. The concordance between 'extrapolated' and traditional breakpoint ranking of these drugs suggests that regression analysis techniques can be used to predict traditional breakpoints.

Alcohol effects on luteinizing hormone-releasing hormone stimulated luteinizing hormone and follicle-stimulating hormone in ovariectomized female rhesus monkeys.

The effects of acute alcohol administration on anterior pituitary function were studied in five ovariectomized female rhesus monkeys. Integrated plasma samples were collected for 80 min before and 120 min after nasogastric intubation of alcohol (2.5 or 3.5 g/kg) or isocaloric sucrose control solution. Then synthetic luteinizing hormone-releasing hormone (LHRH; 100 micrograms/i.v.) was administered and plasma samples were collected for an additional 180 min. After sucrose control administration, LHRH stimulated a significant increase in luteinizing hormone (LH) within 30 min (P less than .001) and follicle-stimulating hormone (FSH) within 60 min (P less than .01). After alcohol administration, LHRH stimulated LH and FSH also increased significantly (P less than .01) when blood alcohol levels averaged 242 (+/- 26) and 296 (+/- 20) mg/dl. Moreover, there was an alcohol dose-dependent increase in LHRH-stimulated LH (P less than .01, .001) in comparison to control conditions, even though prealcohol and presucrose LH levels were equivalent. LHRH-stimulated FSH was also higher after 3.5 g/kg of alcohol than after 2.5 g/kg of alcohol and sucrose control administration (P less than .001) but base-line FSH levels before 3.5 g/kg of alcohol were also higher than control (P less than .05) or 2.5 g/kg of alcohol (P less than .001). An alcohol related enhancement of LHRH-stimulated LH without concomitant suppression of FSH in ovariectomized females contrasts with data reported previously in normally cycling females studied under identical conditions. The absence of ovarian steroid and/or ovarian peptide negative feedback in ovariectomized females may have permitted the synergistic effect of alcohol and LHRH on LH.

Alcohol effects on luteinizing hormone-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone in female rhesus monkeys.

The effects of acute alcohol administration on anterior pituitary function were studied in eight female rhesus monkeys during the follicular phase of the menstrual cycle. Integrated plasma samples were collected for 80 min before and 120 min after nasogastric intubation of alcohol (2.5 or 3.5 g/kg) or isocaloric sucrose control solution. Synthetic luteinizing hormone-releasing hormone (LHRH; 100 micrograms i.v.) was then administered, and plasma samples were collected for an additional 180 min. After sucrose control administration, LHRH stimulated a significant increase in both LH (P less than .001) and follicle-stimulating hormone (FSH) (P less than .004) within 30 and 80 min, respectively. After alcohol administration, LHRH-stimulated LH increased significantly (P less than .001) within 15 min when blood alcohol levels averaged 184 ( +/- 14.3) and 276 ( +/- 14.9)mg/dl. However, FSH levels remained equivalent to base line after alcohol and LHRH administration. The prevention by alcohol of LHRH stimulation of FSH during the follicular phase suggests that alcohol may attenuate normal follicular maturation, which in turn could result in luteal phase inadequacy or anovulation, conditions often observed in alcohol-dependent women and in animal models of alcoholism.